Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics

Emma A. Mol, Zhiyong Lei, Marieke T. Roefs, Maarten H. Bakker, Marie José Goumans, Pieter A. Doevendans, Patricia Y.W. Dankers, Pieter Vader, Joost P.G. Sluijter (Corresponding author)

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)

Abstract

Extracellular vesicles (EVs) are small vesicles secreted by cells and have gained increasing interest as both drug delivery vehicles or as cell-free therapeutics for regenerative medicine. To achieve optimal therapeutic effects, strategies are being developed to prolong EV exposure to target organs. One promising approach to achieve this is through EV-loaded injectable hydrogels. In this study, the use of a hydrogel based on ureido-pyrimidinone (UPy) units coupled to poly(ethylene glycol) chains (UPy-hydrogel) is examined as potential delivery platform for EVs. The UPy-hydrogel undergoes a solution-to-gel transition upon switching from a high to neutral pH, allowing immediate gelation upon administration into physiological systems. Here, sustained EV release from the UPy-hydrogel measured over a period of 4 d is shown. Importantly, EVs retain their functional capacity after release. Upon local administration of fluorescently labeled EVs incorporated in a UPy-hydrogel in vivo, EVs are still detected in the UPy-hydrogel after 3 d, whereas in the absence of a hydrogel, EVs are internalized by fat and skin tissue near the injection site. Together, these data demonstrate that UPy-hydrogels provide sustained EV release over time and enhance local EV retention in vivo, which could contribute to improved therapeutic efficacy upon local delivery and translation toward new applications.

Original languageEnglish
Article number1900847
Number of pages8
JournalAdvanced Healthcare Materials
Volume8
Issue number20
DOIs
Publication statusPublished - 1 Oct 2019

Fingerprint

Pyrimidinones
Hydrogels
Hydrogel
Injections
Therapeutics
Gelation
Extracellular Vesicles
Drug delivery
Polyethylene glycols
Skin
Oils and fats
Regenerative Medicine
Gels
Fats
Ethylene Glycol
Tissue
Therapeutic Uses

Keywords

  • controlled release
  • drug delivery
  • exosomes
  • extracellular vesicles
  • injectable hydrogels

Cite this

Mol, E. A., Lei, Z., Roefs, M. T., Bakker, M. H., Goumans, M. J., Doevendans, P. A., ... Sluijter, J. P. G. (2019). Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics. Advanced Healthcare Materials, 8(20), [1900847]. https://doi.org/10.1002/adhm.201900847
Mol, Emma A. ; Lei, Zhiyong ; Roefs, Marieke T. ; Bakker, Maarten H. ; Goumans, Marie José ; Doevendans, Pieter A. ; Dankers, Patricia Y.W. ; Vader, Pieter ; Sluijter, Joost P.G. / Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics. In: Advanced Healthcare Materials. 2019 ; Vol. 8, No. 20.
@article{c211e89405fd4d4cb3926afe257256ca,
title = "Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics",
abstract = "Extracellular vesicles (EVs) are small vesicles secreted by cells and have gained increasing interest as both drug delivery vehicles or as cell-free therapeutics for regenerative medicine. To achieve optimal therapeutic effects, strategies are being developed to prolong EV exposure to target organs. One promising approach to achieve this is through EV-loaded injectable hydrogels. In this study, the use of a hydrogel based on ureido-pyrimidinone (UPy) units coupled to poly(ethylene glycol) chains (UPy-hydrogel) is examined as potential delivery platform for EVs. The UPy-hydrogel undergoes a solution-to-gel transition upon switching from a high to neutral pH, allowing immediate gelation upon administration into physiological systems. Here, sustained EV release from the UPy-hydrogel measured over a period of 4 d is shown. Importantly, EVs retain their functional capacity after release. Upon local administration of fluorescently labeled EVs incorporated in a UPy-hydrogel in vivo, EVs are still detected in the UPy-hydrogel after 3 d, whereas in the absence of a hydrogel, EVs are internalized by fat and skin tissue near the injection site. Together, these data demonstrate that UPy-hydrogels provide sustained EV release over time and enhance local EV retention in vivo, which could contribute to improved therapeutic efficacy upon local delivery and translation toward new applications.",
keywords = "controlled release, drug delivery, exosomes, extracellular vesicles, injectable hydrogels",
author = "Mol, {Emma A.} and Zhiyong Lei and Roefs, {Marieke T.} and Bakker, {Maarten H.} and Goumans, {Marie Jos{\'e}} and Doevendans, {Pieter A.} and Dankers, {Patricia Y.W.} and Pieter Vader and Sluijter, {Joost P.G.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1002/adhm.201900847",
language = "English",
volume = "8",
journal = "Advanced Healthcare Materials",
issn = "2192-2659",
publisher = "Wiley",
number = "20",

}

Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics. / Mol, Emma A.; Lei, Zhiyong; Roefs, Marieke T.; Bakker, Maarten H.; Goumans, Marie José; Doevendans, Pieter A.; Dankers, Patricia Y.W.; Vader, Pieter; Sluijter, Joost P.G. (Corresponding author).

In: Advanced Healthcare Materials, Vol. 8, No. 20, 1900847, 01.10.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Injectable supramolecular Ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics

AU - Mol, Emma A.

AU - Lei, Zhiyong

AU - Roefs, Marieke T.

AU - Bakker, Maarten H.

AU - Goumans, Marie José

AU - Doevendans, Pieter A.

AU - Dankers, Patricia Y.W.

AU - Vader, Pieter

AU - Sluijter, Joost P.G.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Extracellular vesicles (EVs) are small vesicles secreted by cells and have gained increasing interest as both drug delivery vehicles or as cell-free therapeutics for regenerative medicine. To achieve optimal therapeutic effects, strategies are being developed to prolong EV exposure to target organs. One promising approach to achieve this is through EV-loaded injectable hydrogels. In this study, the use of a hydrogel based on ureido-pyrimidinone (UPy) units coupled to poly(ethylene glycol) chains (UPy-hydrogel) is examined as potential delivery platform for EVs. The UPy-hydrogel undergoes a solution-to-gel transition upon switching from a high to neutral pH, allowing immediate gelation upon administration into physiological systems. Here, sustained EV release from the UPy-hydrogel measured over a period of 4 d is shown. Importantly, EVs retain their functional capacity after release. Upon local administration of fluorescently labeled EVs incorporated in a UPy-hydrogel in vivo, EVs are still detected in the UPy-hydrogel after 3 d, whereas in the absence of a hydrogel, EVs are internalized by fat and skin tissue near the injection site. Together, these data demonstrate that UPy-hydrogels provide sustained EV release over time and enhance local EV retention in vivo, which could contribute to improved therapeutic efficacy upon local delivery and translation toward new applications.

AB - Extracellular vesicles (EVs) are small vesicles secreted by cells and have gained increasing interest as both drug delivery vehicles or as cell-free therapeutics for regenerative medicine. To achieve optimal therapeutic effects, strategies are being developed to prolong EV exposure to target organs. One promising approach to achieve this is through EV-loaded injectable hydrogels. In this study, the use of a hydrogel based on ureido-pyrimidinone (UPy) units coupled to poly(ethylene glycol) chains (UPy-hydrogel) is examined as potential delivery platform for EVs. The UPy-hydrogel undergoes a solution-to-gel transition upon switching from a high to neutral pH, allowing immediate gelation upon administration into physiological systems. Here, sustained EV release from the UPy-hydrogel measured over a period of 4 d is shown. Importantly, EVs retain their functional capacity after release. Upon local administration of fluorescently labeled EVs incorporated in a UPy-hydrogel in vivo, EVs are still detected in the UPy-hydrogel after 3 d, whereas in the absence of a hydrogel, EVs are internalized by fat and skin tissue near the injection site. Together, these data demonstrate that UPy-hydrogels provide sustained EV release over time and enhance local EV retention in vivo, which could contribute to improved therapeutic efficacy upon local delivery and translation toward new applications.

KW - controlled release

KW - drug delivery

KW - exosomes

KW - extracellular vesicles

KW - injectable hydrogels

UR - http://www.scopus.com/inward/record.url?scp=85073951723&partnerID=8YFLogxK

U2 - 10.1002/adhm.201900847

DO - 10.1002/adhm.201900847

M3 - Article

C2 - 31559704

AN - SCOPUS:85073951723

VL - 8

JO - Advanced Healthcare Materials

JF - Advanced Healthcare Materials

SN - 2192-2659

IS - 20

M1 - 1900847

ER -